Breaking News

OsoBio Appoints Manufacturing Director

March 31, 2014

Buck brings 20 years of project management experience

Catherine R. Buck has been appointed director of manufacturing at OsoBio. Ms. Buck is responsible for ensuring operations comply with cGMP as they apply to the manufacture of injectable sterile liquid, suspension and lyophilized pharmaceutical products. Additionally, she will ensure compliance with appropriate FDA regulations, and direct manufacturing activities.
Ms. Buck has more than 20 years of leadership and project management experience within the pharmaceutical, medical device and construction industries, and has managed multiple commercial and clinical pharmaceutical manufacturing plants. Her experience includes the start up, process, equipment and facility validation of a new Amgen manufacturing plant that produced Epogen, as well as obtaining FDA approval of automated equipment and software, and preparing for inspection. Ms. Buck also has managed manufacturing facility operations for Johnson & Johnson and Siemens.
“The same continuous improvement expectations that bear on just about every aspect of industrial productivity exist within pharmaceutical manufacturing as well,” said Milton Boyer, president of OsoBio. “We are fortunate to add someone with Catherine’s breadth of experience to lead a manufacturing team that keeps OsoBio competitive without sacrificing our commitment to quality and cGMP compliance.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important